Q4 FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 12, 2026
Century Therapeutics, Inc. (IPSC) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$20.5 million. As of Jun 30, 2026 it held $197.2 million in cash and investments and $38.7 million in total debt.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-34.55M
-6.2% vs year-ago quarter
Operating cash flow
$-19.83M
+28.1% vs year-ago quarter
Free cash flow
$-20.53M
+26.4% vs year-ago quarter
EPS
$-0.17
+55.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
181.08M
+109.6% vs year-ago quarter
Net cash
$158.52M
Q2 FY2026
Operating margin
-33.1%
Q3 FY2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IPSC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Philadelphia, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1850119
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $109.2M | $0 |
| Operating income | -$36.5M | -$23.7M | -$20.7M | -$36.1M | -$34.7M |
| Net income | -$34.5M | -$21.6M | -$19.2M | -$34.4M | -$32.5M |
| Diluted EPS | -$0.17 | -$0.11 | -$0.22 | -$0.40 | -$0.38 |
| Operating cash flow | -$19.8M | -$25.3M | -$16.1M | -$25.6M | -$27.6M |
| Free cash flow | -$20.5M | -$25.8M | -$16.2M | -$25.8M | -$27.9M |
| Total assets | $287.0M | $326.6M | $223.7M | $244.7M | $284.7M |
| Total liabilities | $54.7M | $61.8M | $64.8M | $68.4M | $74.8M |
| Stockholders' equity | $232.3M | $264.7M | $158.9M | $176.3M | $209.9M |
| Cash and investments | $197.2M | $217.0M | $117.1M | $132.7M | $158.5M |
| Total debt | $38.7M | $48.0M | $43.6M | $45.0M | $51.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 2, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 16, 2026 | Jun 15, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
All 444 Century Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.